文献速递湿疹皮炎与荨麻疹

Spesolimab(一种抗白介素-36受体抗体)治疗中重度特应性皮炎患者:一项多中心、随机、双盲、安慰剂对照IIa期研究结果

Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-01-04

这项IIa期研究将51例中重度特应性皮炎患者按2:1随机分配,每4周静脉注射spesolimab 600 mg或安慰剂。第16周EASI评分较基线下降:spesolimab组-37.9%,安慰剂组-12.3%,校正均值差-25.6%(p=0.149),未达统计学显著。预设敏感性分析排除使用限制性皮质类固醇的患者后,校正均值差为-48.3%(名义p=0.024)。Spesolimab耐受性良好,无临床相关安全性信号。

要点

  • 第16周EASI评分较基线变化:spesolimab组-37.9% vs 安慰剂组-12.3%,校正均值差-25.6%(p=0.149),未达统计学显著。
  • 预设敏感性分析排除使用限制性皮质类固醇的患者后,校正均值差为-48.3%(名义p=0.024)。
  • Spesolimab耐受性良好,未观察到临床相关安全性信号。

核心结论

  • 这是首项评估IL-36通路抑制治疗特应性皮炎的研究;主要终点EASI评分较基线变化虽未达统计学显著,但观察到数值上的改善;spesolimab安全性可接受,无意外安全性问题。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照IIa期研究,51例符合条件的成人中重度特应性皮炎患者按2:1随机分配,每4周静脉注射spesolimab 600 mg或安慰剂。

主要发现

  • 第16周EASI评分较基线下降:spesolimab组-37.9% vs 安慰剂组-12.3%,校正均值差-25.6%(p=0.149)。
  • 预设敏感性分析排除使用限制性皮质类固醇的患者后,校正均值差为-48.3%(名义p=0.024)。
  • Spesolimab耐受性良好,无临床相关安全性信号。

局限性

  • 主要终点EASI评分较基线变化未达统计学显著(校正均值差-25.6%,p=0.149)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease, and there is increasing evidence that the interleukin (IL)-36 pathway may play a role in the pathogenesis of AD. OBJECTIVES: To evaluate the efficacy and safety of spesolimab, a novel anti-IL-36 receptor antibody, in adult patients with moderate-to-severe AD. METHODS: In this phase IIa study, 51 eligible patients were randomized 2:1 to receive intravenous doses of spesolimab 600 mg or placebo every 4 weeks. The primary endpoint was the percentage change from baseline in Eczema Area and Severity Index (EASI) score at Week 16. RESULTS: The decrease in EASI score from baseline to Week 16 was -37.9% for spesolimab versus -12.3% for placebo (adjusted mean difference -25.6%, p = 0.149). A predefined sensitivity analysis, excluding data from patients who used restricted corticosteroids, resulted in an adjusted mean difference of -48.3% (nominal p = 0.024). Spesolimab was well tolerated, with no clinically relevant safety signals. CONCLUSIONS: This is the first study to evaluate the IL-36 pathway inhibition in AD. Although not statistically significant, numerical improvements were observed in the primary endpoint of change from baseline in the EASI score. Spesolimab had an acceptable safety profile, with no unexcepted safety concerns.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Bissonnette R, Abramovits W, Saint-Cyr Proulx É, et al. Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study. J Eur Acad Dermatol Venereol. 2023. PMID: 36376738. doi:10.1111/jdv.18727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。